Multifaceted roles of crystallography in modern drug discovery [electronic resource]
- 作者: NATO Advanced Study Institute on Crystallography in Drug Discovery: a Tool against CBRN Agents (2014 : Erice, Italy)
- 其他作者:
- 其他題名:
- NATO science for peace and security series.
- 出版: Dordrecht : Springer Netherlands :Imprint: Springer
- 叢書名: NATO science for peace and security, series A, Chemistry and biology,
- 主題: Pharmaceutical chemistry--Congresses. , Drugs--Design--Congresses. , Drug development--Congresses. , Crystallography--Congresses. , Structural bioinformatics--Congresses. , Life sciences , Protein-Ligand Interactions. , Medicinal Chemistry. , Molecular Medicine. , Theoretical and Computational Chemistry. , Crystallography
- ISBN: 9789401797191 (electronic bk.) 、 9789401797184 (paper)
- FIND@SFXID: CGU
- 資料類型: 電子書
- 內容註: Preface -- List of Contributors -- Engineering G Protein-Coupled Receptors for Drug Design -- Structural Insights into Activation and Allosteric Modulation of G Protein-Coupled Receptors -- Epigenetic Drug Discovery -- Crystallography and Biopharmaceuticals -- Structural Chemistry and Molecular Modeling in the Design of DPP4 Inhibitors -- Considerations for Structure-Based Drug Design Targeting HIV-1 Reverse Transcriptase.-Protein-Ligand Interactions as the Basis for Drug Action -- The Protein Data Bank: Overview and Tools for Drug Discovery -- Small Molecule Crystal Structures in Drug Discovery -- Protein Aggregation and its Prediction -- Importance of Protonation States for the Binding of Ligands to Pharmaceutical Targets -- Protein-Protein Interactions: Structures and Druggability -- Achieving High Quality Ligand Chemistry in Protein-Ligand Crystal Structures for Drug Design -- Molecular Obesity, Potency and Other Addictions in Drug Discovery -- Adventures in Small Molecule Fragment Screening by X-ray Crystallography for Drug Discovery -- Structure-Based Drug Design to Perturb Function of a tRNA-Modifying Enzyme by Active Site and Protein-Protein Interface Inhibition -- Molecular Interaction Analysis for Discovery of Drugs Targeting Enzymes and for Resolving Biological Function.
- 摘要註: The present work offers a snapshot of the state-of-the-art of crystallographic, analytical, and computational methods used in modern drug design and development. Topics discussed include: drug design against complex systems (membrane proteins, cell surface receptors, epigenetic targets, and ribosomes); modulation of protein-protein interactions; the impact of small molecule structures in drug discovery and the application of concepts such as molecular geometry, conformation, and flexibility to drug design; methodologies for understanding and characterizing protein states and protein-ligand interactions during the drug design process; and monoclonal antibody therapies. These methods are illustrated through their application to problems of medical and biological significance, such as viral and bacterial infections, diabetes, autoimmune disease, and CNS diseases. As approaches to drug discovery have changed over time, so have the methodologies used to solve the varied, new, and difficult problems encountered in drug discovery. In recent years we have seen great progress in the fields of genetics, biology, chemistry, and medicine, but there are still many unmet medical needs, from bacterial infections to cancer to chronic maladies, that require novel, different, or better therapies. This work will be of interest to researchers and policy makers interested in the latest developments in drug design.
-
讀者標籤:
- 系統號: 005127936 | 機讀編目格式
館藏資訊
The present work offers a snapshot of the state-of-the-art of crystallographic, analytical, and computational methods used in modern drug design and development. Topics discussed include: drug design against complex systems (membrane proteins, cell surface receptors, epigenetic targets, and ribosomes); modulation of protein-protein interactions; the impact of small molecule structures in drug discovery and the application of concepts such as molecular geometry, conformation, and flexibility to drug design; methodologies for understanding and characterizing protein states and protein-ligand interactions during the drug design process; and monoclonal antibody therapies. These methods are illustrated through their application to problems of medical and biological significance, such as viral and bacterial infections, diabetes, autoimmune disease, and CNS diseases. As approaches to drug discovery have changed over time, so have the methodologies used to solve the varied, new, and difficult problems encountered in drug discovery. In recent years we have seen great progress in the fields of genetics, biology, chemistry, and medicine, but there are still many unmet medical needs, from bacterial infections to cancer to chronic maladies, that require novel, different, or better therapies. This work will be of interest to researchers and policy makers interested in the latest developments in drug design.